Mertz G J, Ashley R, Burke R L, Benedetti J, Critchlow C, Jones C C, Corey L
Department of Laboratory Medicine, University of Washington, Seattle.
J Infect Dis. 1990 Apr;161(4):653-60. doi: 10.1093/infdis/161.4.653.
To determine the efficacy of a herpes simplex virus type 2 (HSV-2) glycoprotein subunit vaccine, vaccine (50 micrograms) or placebo was administered intramuscularly at weeks 0, 4, and 22 to 161 persons who lacked HSV-2 antibodies and were sex partners of persons with recurrent genital herpes. The annual rate of acquisition of HSV infection was similar among vaccine and placebo recipients (10.7% and 8%, respectively) but was higher in initially seronegative subjects (15.5%) than in those with HSV-1 at entry (5.9%). Eleven (79%) of the 14 HSV infections acquired during follow-up were symptomatic. Vaccination elicited ELISA antibody titers to glycoproteins gD2 and gB2 that were only 10% and 5%, respectively, of titers found in persons with recurrent genital HSV-2 infection. This vaccine failed to provide protection from acquisition of genital HSV infection. The lack of efficacy appears to be related, in part, to the poor immunogenicity of the vaccine.
为确定2型单纯疱疹病毒（HSV - 2）糖蛋白亚单位疫苗的疗效，对161名缺乏HSV - 2抗体且为复发性生殖器疱疹患者性伴侣的人，于第0、4和22周肌肉注射疫苗（50微克）或安慰剂。疫苗接种者和安慰剂接受者中HSV感染的年发生率相似（分别为10.7%和8%），但初始血清阴性的受试者（15.5%）的发生率高于入组时已有HSV - 1感染的受试者（5.9%）。随访期间获得的14例HSV感染中有11例（79%）出现症状。接种疫苗后引发的针对糖蛋白gD2和gB2的ELISA抗体滴度，分别仅为复发性生殖器HSV - 2感染患者中所测滴度的10%和5%。该疫苗未能预防生殖器HSV感染。疗效欠佳似乎部分与疫苗免疫原性较差有关。
